Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 1 Nov 2005

Sax Paul E, Islam Runa, Walensky Rochelle P, Losina Elena, Weinstein Milton C, Goldie Sue J, Sadownik Sara N, Freedberg Kenneth A

Abstract excerpt

BACKGROUND: Data from the United States and Europe show a population prevalence of baseline drug resistance of 8%-10% among human immunodeficiency virus (HIV)-infected patients who are antiretroviral naive. Our objective was to determine the clinical impact and cost-effectiveness of genotype resistance testing for treatment-naive patients with chronic HIV infection. METHODS: We utilized a state-transition model...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Retroviral Agents
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Genotype

Share to HIV Infections

Share to Microbial Sensitivity Tests

Source

Identifiers

PMID: 16206108
DOI: 10.1086/496984

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.PMID 16206108Read ↗

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.Semantic proximity Read ↗

The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach.Semantic proximity Read ↗

Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virological failure: A meta-analysis.Semantic proximity Read ↗

Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.Semantic proximity Read ↗

The cost of antiretroviral drug resistance in HIV-positive patients.Semantic proximity Read ↗

The Prevalence of Transmitted Resistance to First-Generation Non-Nucleoside Reverse Transcriptase Inhibitors and Its Potential Economic Impact in HIV-Infected PatientsSemantic proximity Read ↗

Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysisSemantic proximity Read ↗

Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.Semantic proximity Read ↗

Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study.Semantic proximity Read ↗

Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United StatesSemantic proximity Read ↗

The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.Semantic proximity Read ↗

Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.